Printer Friendly

Company offers stem cell therapy coupled with hyperbaric oxygen treatment.

TAMPA, Fla., February. 20, 2017 -- Stemedix Inc., said it is now offering patients a neurological treatment that combines hyperbaric oxygen therapy (HBOT) and fat-derived stem cell therapy.

Studies have described the benefit of having HBOT treatments in conjunction with stem cell therapy is increasing the synthesis of nitric oxide, which signals the release of stem cells.

A recent study by researchers from Neural Regeneration Research found that test subjects that underwent both mesenchymal stem cell transplantation and HBOT had better neurological outcomes and better cognitive performance scores than subjects that endured only one type of treatment.

Another study at the University of Pennsylvania School of Medicine, led by researcher Stephen Thorn, found that HBOT increases stem cell activity.

After one treatment, the stem cell concentration doubled and after 20 treatments increased eightfold.

Stemedix's combination of stem cell therapy treatments with HBOT allows healing to occur that enables fibroblasts (tissue cells), capillaries (circulatory), osteoblasts (bone cells) and stem cells to be stimulated.

Without appropriate levels of oxygen in the tissue, healing cannot take place.

With HBOT, oxygen is dissolved into all of the body's fluids, plasma, central nervous system fluids, lymph, and bone. In addition, the areas of the body that are lacking oxygen will begin to receive oxygen again.

A Closer Look At Stemedix And Its Stem Cell Therapies

Stemedix offers adipose (fat-derived) stem cell treatments for ALS, multiple sclerosis, osteoarthritis, nerve damage, COPD, etc.

A website (Investigation on Stemedix) that researches clinics offering stem cell treatments said this about Stemedix:

"Final verdict: unproven treatment. Sketchy media. Questionable doctor. Misleading portrayal of research and information. Stemedix may very well be out for your money. Err on the side of caution."

One commenter (Elaine James) on this website who read the analysis of Stemedix said:

"My husband has ALS. If stem cell treatment/therapy is not going to help him, we are not interested in pursuing stem cell treatment/therapy. We were going to be out at least $25,000 and possibly more."

The Stemedix website lists a number of patient treatment reviews. Most indicate how pleasant the experience was, how nice the staff and physician and hotel were, etc.

But some mention vague anecdotal results:

* MS patient: "I will recommend more once I can determine if this therapy has worked for me since it's still a bit too early in the process to tell."

* MS patient: "I am already noticing some results from my first treatment."

* Unknown illness: "Within a week I was pain free and felt my balance was improved. I can't walk yet..."

* MS patient: "After the procedure my tremors subsided and could stand much better."

* Unknown illness: "I continue to remain positive and hopeful. The most incredible back spasms set me back, but they are passing and I am moving forward. (Not sure of the cause of the spasms.) The experience was wonderful and stressful, but everyone there helped alleviate the stress."

None of the reviews mention the name of a physician or any staff member. There was no mention of controlled clinical trials.

One reviewer complained about the WiFi system at the hotel. Otherwise, the reviews sounded like evaluations of a nice, if a little stressful and expensive, Florida vacation for desperate gullible people with access to a lot of money.

In other words: Caveat emptor.


COPYRIGHT 2017 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Advanced Stem Cell Technologies
Publication:Stem Cell Business News
Geographic Code:1U5FL
Date:Mar 6, 2017
Previous Article:Positive clinical trial results in stem cell selection technology for transplantation.
Next Article:&2.29M to fund animal studies of therapy for knee osteoarthritis.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters